Foster & Motley Inc. Cuts Holdings in Organon & Co. (NYSE:OGN)

Foster & Motley Inc. reduced its position in Organon & Co. (NYSE:OGN) by 4.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,699 shares of the company’s stock after selling 1,308 shares during the period. Foster & Motley Inc.’s holdings in Organon & Co. were worth $383,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Prospera Private Wealth LLC purchased a new stake in shares of Organon & Co. during the 3rd quarter worth approximately $25,000. Horizon Bancorp Inc. IN increased its position in Organon & Co. by 2,401.5% in the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock worth $25,000 after purchasing an additional 1,585 shares during the last quarter. Abich Financial Wealth Management LLC raised its stake in Organon & Co. by 5,646.3% during the third quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock valued at $45,000 after purchasing an additional 2,315 shares in the last quarter. Trust Co. of Vermont lifted its position in Organon & Co. by 109.4% during the third quarter. Trust Co. of Vermont now owns 2,626 shares of the company’s stock valued at $50,000 after purchasing an additional 1,372 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its stake in shares of Organon & Co. by 32.4% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock worth $41,000 after buying an additional 672 shares in the last quarter. 77.43% of the stock is owned by institutional investors.

Organon & Co. Stock Down 2.4 %

Shares of OGN opened at $15.59 on Friday. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The business has a fifty day moving average of $15.47 and a 200 day moving average of $17.93. The company has a market cap of $4.01 billion, a PE ratio of 3.09, a P/E/G ratio of 0.89 and a beta of 0.76. Organon & Co. has a 52-week low of $13.87 and a 52-week high of $23.10.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, October 31st. The company reported $0.87 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.03). Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The firm had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.56 billion. During the same period in the prior year, the company posted $0.78 EPS. The company’s revenue was up 4.1% compared to the same quarter last year. On average, sell-side analysts expect that Organon & Co. will post 3.83 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $21.33.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.